ALZN

Alzamend Neuro, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website alzamend.com
Employees(FY) 4
ISIN US02262M5067

Performance

-6.72%

-20.71%

-36.57%

-72.18%

-87.53%

YTD

-86.81%

Profile

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Advanced Technical Analysis

Technical Analysis of ALZN 2024-12-20

The stock indicators reflect a bearish sentiment overall, with the Moving Average Score at 3 indicating strong downward pressure, while the Oscillators Score of 46 suggests a neutral stance, and the Technical Score of 25 reinforces the bearish outlook. This combination signals caution for potential investors, as the prevailing trend appears to b...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ALZN

Stock Rank

Recent News & Updates

2024-12-17 19:00
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo(Businesswire)
2024-12-12 19:15
Alzamend Neuro says net cash gained by financing activity $8.3M(Yahoo Finance)
2024-12-11 19:00
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs(Businesswire)
2024-11-18 19:00
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimers Transgenic Mice(Businesswire)
2024-11-18 18:30
EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential(Yahoo Finance)
2024-10-15 20:00
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers(Businesswire)
2024-10-15 19:30
EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's(Yahoo Finance)
2024-10-14 20:00
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards(Businesswire)
2024-10-09 20:00
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Groups Virtual Healthcare Conference(Businesswire)
2024-08-25 20:00
Alzamend Neuro Issues Letter to Stockholders(Businesswire)
2024-08-18 20:00
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder(Businesswire)
2024-08-11 20:00
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder(Businesswire)
2024-08-05 20:00
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder(Businesswire)
2024-08-05 17:32
Alzamend Neuro partners with Mass General for Alzheimers treatment trial(Yahoo Finance)
2024-08-04 21:09
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimers Disease(Businesswire)
2024-08-04 19:30
EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study(Yahoo Finance)
2024-07-30 20:00
Alzamend Neuro Regains Compliance with Nasdaqs Minimum Bid Price Requirement(Businesswire)
2024-07-11 20:00
Alzamend Neuro Announces Reverse Stock Split(Businesswire)
2024-05-21 20:00
Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel(Businesswire)
2024-05-13 20:00
Alzamend Neuro Announces Initial Closing of Private Placement(Businesswire)
2024-05-08 21:30
EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares(Yahoo Finance)
2024-05-08 20:00
Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million(Businesswire)
2024-05-06 20:00
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program(Businesswire)
2024-04-02 05:41
Insiders Are Buying These 11 Penny Stocks(Insidermonkey)
2024-03-25 17:52
ALZN Stock Earnings: Alzamend Neuro Misses EPS for Q3 2024(Investorplace)
2023-12-17 23:03
ALZN Stock Earnings: Alzamend Neuro Beats EPS for Q1 2024(Investorplace)
2023-12-17 23:03
ALZN Stock Earnings: Alzamend Neuro Reported Results for Q2 2024(Investorplace)
2023-12-10 20:30
EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year(Yahoo Finance)
2023-12-10 19:00
Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients(Businesswire)
2023-11-19 19:00
Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients(Businesswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.